Safety of the Up-titration of Nifedipine GITS and Valsartan or Low-dose Combination in Uncontrolled Hypertension: The FOCUS Study

Jeong Bae Park, Joon Han Shin, Dong Soo Kim, Ho Joong Youn, Seung Woo Park, Wan Joo Shim, Chang Gyu Park, Dong Woon Kim, Hae Young Lee, Dong Ju Choi, Se Joong Rim, Sung Yun Lee, Ju Han Kim

Research output: Contribution to journalArticle

Abstract

Purpose Doubling the dose of antihypertensive drugs is necessary to manage hypertension in patients whose disease is uncontrolled. However, this strategy can result in safety issues. This study compared the safety and efficacy of up-titration of the nifedipine gastrointestinal therapeutic system (GITS) with up-titration of valsartan monotherapy; these were also compared with low-dose combinations of the two therapies. Methods This prospective, open-label, randomized, active-controlled, multicenter study lasted 8 weeks. If patients did not meet the target blood pressure (BP) after 4 weeks of treatment with low-dose monotherapy, they were randomized to up-titration of the nifedipine GITS dose from 30 mg (N30) to 60 mg or valsartan from 80 mg to 160 mg or they were randomized to receive a low-dose combination of N30 and valsartan 80 mg for another 4 weeks. BP variability was assessed by using the SD or the %CV of the short-term BP measured at clinic. Findings Of the 391 patients (20~70 years with stage II or higher hypertension) screened for study inclusion, 362 patients who had 3 BP measurements were enrolled. The reduction in the mean systolic/diastolic BP from baseline to week 4 was similar in both low-dose monotherapy groups with either N30 or valsartan 80 mg. BP variability (SD) was unchanged with either therapy, but the %CV was slightly increased in the N30 group. There was no significant difference in BP variability either in SD or %CV between responders and nonresponders to each monotherapy despite the significant difference in the mean BP changes. The up-titration effect of nifedipine GTS from 30 to 60 mg exhibited an additional BP reduction, but this effect was not shown in the up-titration of valsartan from 80 to 160 mg. Although the difference in BP was obvious between high-dose nifedipine GTS and valsartan, the BP variability was unchanged between the 2 drugs and was similar to the low-dose combinations. There was a low rate of adverse events in all treatment groups. In addition, escalating the dose of either nifedipine GITS or valsartan revealed a similar occurrence of adverse effects with low-dose monotherapy or the low-dose combination. Implications Compared with up-titration of the angiotensin receptor blocker valsartan, up-titration of the calcium channel blocker nifedipine GITS provided no additional increased safety concerns and revealed better mean reductions in BP without affecting short-term BP variability.

Original languageEnglish
Pages (from-to)832-842
Number of pages11
JournalClinical Therapeutics
Volume38
Issue number4
DOIs
Publication statusPublished - 2016 Apr 1

Fingerprint

Valsartan
Nifedipine
Blood Pressure
Hypertension
Safety
Therapeutics

Keywords

  • angiotensin receptor blocker
  • antihypertensive agents
  • BP variability
  • calcium channel blocker
  • hypertension
  • safety

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Safety of the Up-titration of Nifedipine GITS and Valsartan or Low-dose Combination in Uncontrolled Hypertension : The FOCUS Study. / Park, Jeong Bae; Shin, Joon Han; Kim, Dong Soo; Youn, Ho Joong; Park, Seung Woo; Shim, Wan Joo; Park, Chang Gyu; Kim, Dong Woon; Lee, Hae Young; Choi, Dong Ju; Rim, Se Joong; Lee, Sung Yun; Kim, Ju Han.

In: Clinical Therapeutics, Vol. 38, No. 4, 01.04.2016, p. 832-842.

Research output: Contribution to journalArticle

Park, JB, Shin, JH, Kim, DS, Youn, HJ, Park, SW, Shim, WJ, Park, CG, Kim, DW, Lee, HY, Choi, DJ, Rim, SJ, Lee, SY & Kim, JH 2016, 'Safety of the Up-titration of Nifedipine GITS and Valsartan or Low-dose Combination in Uncontrolled Hypertension: The FOCUS Study', Clinical Therapeutics, vol. 38, no. 4, pp. 832-842. https://doi.org/10.1016/j.clinthera.2016.02.025
Park, Jeong Bae ; Shin, Joon Han ; Kim, Dong Soo ; Youn, Ho Joong ; Park, Seung Woo ; Shim, Wan Joo ; Park, Chang Gyu ; Kim, Dong Woon ; Lee, Hae Young ; Choi, Dong Ju ; Rim, Se Joong ; Lee, Sung Yun ; Kim, Ju Han. / Safety of the Up-titration of Nifedipine GITS and Valsartan or Low-dose Combination in Uncontrolled Hypertension : The FOCUS Study. In: Clinical Therapeutics. 2016 ; Vol. 38, No. 4. pp. 832-842.
@article{91118b7ab02d47e2aa8c9def24383daf,
title = "Safety of the Up-titration of Nifedipine GITS and Valsartan or Low-dose Combination in Uncontrolled Hypertension: The FOCUS Study",
abstract = "Purpose Doubling the dose of antihypertensive drugs is necessary to manage hypertension in patients whose disease is uncontrolled. However, this strategy can result in safety issues. This study compared the safety and efficacy of up-titration of the nifedipine gastrointestinal therapeutic system (GITS) with up-titration of valsartan monotherapy; these were also compared with low-dose combinations of the two therapies. Methods This prospective, open-label, randomized, active-controlled, multicenter study lasted 8 weeks. If patients did not meet the target blood pressure (BP) after 4 weeks of treatment with low-dose monotherapy, they were randomized to up-titration of the nifedipine GITS dose from 30 mg (N30) to 60 mg or valsartan from 80 mg to 160 mg or they were randomized to receive a low-dose combination of N30 and valsartan 80 mg for another 4 weeks. BP variability was assessed by using the SD or the {\%}CV of the short-term BP measured at clinic. Findings Of the 391 patients (20~70 years with stage II or higher hypertension) screened for study inclusion, 362 patients who had 3 BP measurements were enrolled. The reduction in the mean systolic/diastolic BP from baseline to week 4 was similar in both low-dose monotherapy groups with either N30 or valsartan 80 mg. BP variability (SD) was unchanged with either therapy, but the {\%}CV was slightly increased in the N30 group. There was no significant difference in BP variability either in SD or {\%}CV between responders and nonresponders to each monotherapy despite the significant difference in the mean BP changes. The up-titration effect of nifedipine GTS from 30 to 60 mg exhibited an additional BP reduction, but this effect was not shown in the up-titration of valsartan from 80 to 160 mg. Although the difference in BP was obvious between high-dose nifedipine GTS and valsartan, the BP variability was unchanged between the 2 drugs and was similar to the low-dose combinations. There was a low rate of adverse events in all treatment groups. In addition, escalating the dose of either nifedipine GITS or valsartan revealed a similar occurrence of adverse effects with low-dose monotherapy or the low-dose combination. Implications Compared with up-titration of the angiotensin receptor blocker valsartan, up-titration of the calcium channel blocker nifedipine GITS provided no additional increased safety concerns and revealed better mean reductions in BP without affecting short-term BP variability.",
keywords = "angiotensin receptor blocker, antihypertensive agents, BP variability, calcium channel blocker, hypertension, safety",
author = "Park, {Jeong Bae} and Shin, {Joon Han} and Kim, {Dong Soo} and Youn, {Ho Joong} and Park, {Seung Woo} and Shim, {Wan Joo} and Park, {Chang Gyu} and Kim, {Dong Woon} and Lee, {Hae Young} and Choi, {Dong Ju} and Rim, {Se Joong} and Lee, {Sung Yun} and Kim, {Ju Han}",
year = "2016",
month = "4",
day = "1",
doi = "10.1016/j.clinthera.2016.02.025",
language = "English",
volume = "38",
pages = "832--842",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "4",

}

TY - JOUR

T1 - Safety of the Up-titration of Nifedipine GITS and Valsartan or Low-dose Combination in Uncontrolled Hypertension

T2 - The FOCUS Study

AU - Park, Jeong Bae

AU - Shin, Joon Han

AU - Kim, Dong Soo

AU - Youn, Ho Joong

AU - Park, Seung Woo

AU - Shim, Wan Joo

AU - Park, Chang Gyu

AU - Kim, Dong Woon

AU - Lee, Hae Young

AU - Choi, Dong Ju

AU - Rim, Se Joong

AU - Lee, Sung Yun

AU - Kim, Ju Han

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Purpose Doubling the dose of antihypertensive drugs is necessary to manage hypertension in patients whose disease is uncontrolled. However, this strategy can result in safety issues. This study compared the safety and efficacy of up-titration of the nifedipine gastrointestinal therapeutic system (GITS) with up-titration of valsartan monotherapy; these were also compared with low-dose combinations of the two therapies. Methods This prospective, open-label, randomized, active-controlled, multicenter study lasted 8 weeks. If patients did not meet the target blood pressure (BP) after 4 weeks of treatment with low-dose monotherapy, they were randomized to up-titration of the nifedipine GITS dose from 30 mg (N30) to 60 mg or valsartan from 80 mg to 160 mg or they were randomized to receive a low-dose combination of N30 and valsartan 80 mg for another 4 weeks. BP variability was assessed by using the SD or the %CV of the short-term BP measured at clinic. Findings Of the 391 patients (20~70 years with stage II or higher hypertension) screened for study inclusion, 362 patients who had 3 BP measurements were enrolled. The reduction in the mean systolic/diastolic BP from baseline to week 4 was similar in both low-dose monotherapy groups with either N30 or valsartan 80 mg. BP variability (SD) was unchanged with either therapy, but the %CV was slightly increased in the N30 group. There was no significant difference in BP variability either in SD or %CV between responders and nonresponders to each monotherapy despite the significant difference in the mean BP changes. The up-titration effect of nifedipine GTS from 30 to 60 mg exhibited an additional BP reduction, but this effect was not shown in the up-titration of valsartan from 80 to 160 mg. Although the difference in BP was obvious between high-dose nifedipine GTS and valsartan, the BP variability was unchanged between the 2 drugs and was similar to the low-dose combinations. There was a low rate of adverse events in all treatment groups. In addition, escalating the dose of either nifedipine GITS or valsartan revealed a similar occurrence of adverse effects with low-dose monotherapy or the low-dose combination. Implications Compared with up-titration of the angiotensin receptor blocker valsartan, up-titration of the calcium channel blocker nifedipine GITS provided no additional increased safety concerns and revealed better mean reductions in BP without affecting short-term BP variability.

AB - Purpose Doubling the dose of antihypertensive drugs is necessary to manage hypertension in patients whose disease is uncontrolled. However, this strategy can result in safety issues. This study compared the safety and efficacy of up-titration of the nifedipine gastrointestinal therapeutic system (GITS) with up-titration of valsartan monotherapy; these were also compared with low-dose combinations of the two therapies. Methods This prospective, open-label, randomized, active-controlled, multicenter study lasted 8 weeks. If patients did not meet the target blood pressure (BP) after 4 weeks of treatment with low-dose monotherapy, they were randomized to up-titration of the nifedipine GITS dose from 30 mg (N30) to 60 mg or valsartan from 80 mg to 160 mg or they were randomized to receive a low-dose combination of N30 and valsartan 80 mg for another 4 weeks. BP variability was assessed by using the SD or the %CV of the short-term BP measured at clinic. Findings Of the 391 patients (20~70 years with stage II or higher hypertension) screened for study inclusion, 362 patients who had 3 BP measurements were enrolled. The reduction in the mean systolic/diastolic BP from baseline to week 4 was similar in both low-dose monotherapy groups with either N30 or valsartan 80 mg. BP variability (SD) was unchanged with either therapy, but the %CV was slightly increased in the N30 group. There was no significant difference in BP variability either in SD or %CV between responders and nonresponders to each monotherapy despite the significant difference in the mean BP changes. The up-titration effect of nifedipine GTS from 30 to 60 mg exhibited an additional BP reduction, but this effect was not shown in the up-titration of valsartan from 80 to 160 mg. Although the difference in BP was obvious between high-dose nifedipine GTS and valsartan, the BP variability was unchanged between the 2 drugs and was similar to the low-dose combinations. There was a low rate of adverse events in all treatment groups. In addition, escalating the dose of either nifedipine GITS or valsartan revealed a similar occurrence of adverse effects with low-dose monotherapy or the low-dose combination. Implications Compared with up-titration of the angiotensin receptor blocker valsartan, up-titration of the calcium channel blocker nifedipine GITS provided no additional increased safety concerns and revealed better mean reductions in BP without affecting short-term BP variability.

KW - angiotensin receptor blocker

KW - antihypertensive agents

KW - BP variability

KW - calcium channel blocker

KW - hypertension

KW - safety

UR - http://www.scopus.com/inward/record.url?scp=84961233503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961233503&partnerID=8YFLogxK

U2 - 10.1016/j.clinthera.2016.02.025

DO - 10.1016/j.clinthera.2016.02.025

M3 - Article

C2 - 26996246

AN - SCOPUS:84961233503

VL - 38

SP - 832

EP - 842

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 4

ER -